China Glioblastoma Multiforme Treatment Market Size & Outlook, 2030

The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to glioblastoma multiforme treatment market will help companies and investors design strategic landscapes.

The Chinese government offers advanced infrastructure facilities to foreign investors. In addition, easy availability of cheap labor contributes to the expansion of market players in this country. The focus of major market players on China is likely to aid market growth over the forecast period. Increasing initiatives undertaken by market players to develop new treatment options for brain cancer are expected to propel the market growth in the country.

In 2018, GBM accounted for 17% of newly diagnosed brain and nervous system cancers in China, as reported by WHO. I-Mab, a Chinese company, is developing a novel long-acting recombinant human interleukin-7 (rhIL-7), for GBM treatment in China. Moreover, CANbridge Life Sciences’ IND application for a Phase II/III clinical study of lead candidate, CAN008, was approved by China FDA. The clinical trial will evaluate safety and efficacy of weekly CAN008 + re-radiation therapy (rRT) in GBM patients.

Reasons to subscribe to China glioblastoma multiforme treatment market databook:

Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.

Target buyers of China glioblastoma multiforme treatment market databook

Our clientele includes a mix of glioblastoma multiforme treatment market companies, investment firms, advisory firms & academic institutions.
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.

Horizon Databook provides a detailed overview of country-level data and insights on the China glioblastoma multiforme treatment market , including forecasts for subscribers. This country databook contains high-level insights into China glioblastoma multiforme treatment market from 2018 to 2030, including revenue numbers, major trends, and company profiles.

Partial client list